Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Morgan Stanley Maintains Equal-Weight on Sarepta Therapeutics, Raises Price Target to $92

Morgan Stanley maintains Sarepta Therapeutics (NASDAQ:SRPT) with a Equal-Weight and raises the price target from $90 to $92.

byBenzinga Newsdesk

January 18, 2022

1 minute read

Morgan Stanley maintains Sarepta Therapeutics (NASDAQ:SRPT) with a Equal-Weight and raises the price target from $90 to $92.

Ascendiant Capital Initiates Coverage On Lucid Diagnostics with Buy Rating, Announces Price Target of $16

By Benzinga Newsdesk

Today, 3:10 AM

Ascendiant Capital analyst Edward Woo initiates coverage on Lucid Diagnostics (NASDAQ:LUCD) with a Buy rating and announces Price Target of $16.

LUCD

HC Wainwright & Co. Maintains Buy on Arqit Quantum, Lowers Price Target to $10

By Benzinga Newsdesk

Today, 3:10 AM

HC Wainwright & Co. analyst Scott Buck maintains Arqit Quantum (NASDAQ:ARQQ) with a Buy and lowers the price target from $14 to $10.

ARQQ

Maersk And Canadian Pacific Open Vancouver Transload Facility

By FreightWaves

Today, 3:10 AM

A transload facility at Vancouver developed by Maersk and Canadian Pacific is open for business.

Veru Posts Mixed Q4 Results

By Shivani Kumaresan

Today, 3:10 AM

Veru Inc (NASDAQ:VERU) reported fourth-quarter FY21 sales growth of 32.8% year-on-year, to $15.65 million, missing the analyst consensus of $18.17 million.…

VERU

Morgan Stanley Maintains Equal-Weight on Sarepta Therapeutics, Raises Price Target to $92

Related Posts

Ascendiant Capital Initiates Coverage On Lucid Diagnostics with Buy Rating, Announces Price Target of $16

HC Wainwright & Co. Maintains Buy on Arqit Quantum, Lowers Price Target to $10

Maersk And Canadian Pacific Open Vancouver Transload Facility

Veru Posts Mixed Q4 Results